MAMeredith A. Achey

Meredith A. Achey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Meredith A. Achey has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Congenital Diaphragmatic Hernia Repair at the Bedside or Operating Theater

    by Jan A. Niec, Meredith A. Achey, Marshall W. Wallace, Anuradha Patel, Shilin Zhao, L. Dupree Hatch, Emily A. Morris, Melissa E. Danko, John B. Pietsch, Harold N. Lovvorn

    Background: For critically ill congenital diaphragmatic hernia (CDH) patients on high frequency oscillatory ventilation (HFOV), extracorporeal membrane oxygenation (ECMO), and/or inhaled nitric oxide (iNO), operative repair in the neonatal intensive care unit (NICU) has been proposed to avoid complications during transport to an operating room (OR). This study compared neonates with CDH who received herniorrhaphy in the NICU or OR, with a subgroup analysis considering only patients supported with ECMO. Methods: Patients admitted to the NICU in the first 2 weeks of life at a free-standing children’s hospital between July 2004 and September 2021 were examined. Patients were categorized according to location of CDH repair, and impact on operative complications and survival was compared. Results: 185 patients were admitted to the NICU with posterolateral CDH and received operative repair. 48 cases were operated on at the bedside in the NICU and 137 in the OR. Patients repaired in the NICU had higher use of HFOV, pulmonary vasodilators, and ECMO (all P < .001). Children repaired in the NICU experienced significantly higher in-hospital death and overall mortality ( P < .001). However, in multivariate analysis, repair location was not a significant predictor of survival to discharge in patients receiving ECMO. No significant difference in surgical site infection was detected for operative location ( P = .773). Discussion: Congenital diaphragmatic hernia repair in the NICU occurred more frequently among higher risk patients who experienced worse survival. The rate of surgical site infection appeared similar overall and across subgroups suggesting adequate sterility and technique for bedside procedures, when necessary, despite restricted access to advanced operative equipment.


  • Non-inferiority of fragmented care for high-risk pediatric neuroblastoma patients: a single institution analysis

    by Aaron M. Tarnasky, Meredith A. Achey, Luke P. Wachsmuth, Hannah Williamson, Samantha M. Thomas, Sarah Jane Commander, Harold Leraas, Tim Driscoll, Elisabeth T. Tracy

    Pediatric neuroblastoma (NB) patients receive multi-modal therapy and may experience care fragmented among multiple institutions with a significant travel burden, which has been associated with poor outcomes for some adult cancers. We hypothesized that fragmented care for pediatric NB patients is associated with inferior outcomes compared to treatment consolidated at one location. We reviewed paper and electronic records for pediatric NB patients who received ≥1 hematopoietic stem cell transplant (HSCT) at Duke from 1990-2017. Fragmented care was defined by treatment at >1 institution and grouped by 2 institutions vs. 3+ institutions. Distances were calculated using Google Maps. To compare all care groups, we used Fisher’s Exact and Kruskal-Wallis tests for demographic and treatment characteristics, Kaplan-Meier for unadjusted overall survival (OS), and Cox proportional hazards for factors associated with OS. Of 127 eligible patients, 102 (80.3%) patients experienced fragmented care, with 17 treated at 3+ facilities. Kaplan-Meier analysis did not associate fragmented care with increased mortality (log-rank p = 0.13). With multivariate analysis, only earlier diagnostic decade and greater distance to HSCT remained significantly associated with worsened OS. In this single institutional study, we found fragmented care did not impact overall survival. Worsened overall survival was associated with increased travel distance for HSCT and further research should aim to improve supportive processes for patients undergoing HSCT for high-risk neuroblastoma.


  • Open Access

    Hepatic vascular malignancies in children are associated with increased rates of surgical resection and improved overall survival compared with adults

    by Sarah Jane Commander, Marcelo Cerullo, Harold J. Leraas, Christopher R. Reed, Meredith A. Achey, Lucas P. Wachsmuth, Gary R. Schooler, Elisabeth T. Tracy

    Background: Hepatic vascular malignancies (HVMs) are rare malignancies, with no standardized treatment regimens. The most common HVMs, angiosarcoma and malignant epithelioid hemangioendothelioma (EHE), are often grouped together in the literature complicating our ability to achieve reliable survival data and treatment strategies.Objective: To compare the disease characteristics of HVMs, with a subanalysis on pediatric patients.Methods: The 2016 National Cancer Database was queried for patients with HVMs using international classification of diseases‐oncology‐3 (ICD‐O‐3) codes yielding 699 patients. Descriptive statistics, chi‐square, Kaplan‐Meier, and log‐rank analyses were performed.Results: We found 478 patients (68%) with angiosarcoma and 221 (32%) with EHE. The median (Q1, Q3) age for angiosarcoma patients was 65 years (56, 75) versus 54 years (37, 65) in EHE patients (P < .001). The rate of resection was lower in patients with angiosarcoma than EHE (13% vs 32%, P < .001). The mean 1‐, 3‐, and 5‐year overall survival for angiosarcoma patients was 17%, 8%, and 6%, respectively, versus 80%, 65%, and 62% in EHE patients (P < .0001). A subgroup analysis was performed on pediatric patients demonstrating six with angiosarcoma and 10 with EHE. The mean 1‐, 3‐, and 5‐year overall survival for pediatric angiosarcoma patients was 67%, 50%, and 50%, respectively, and 90%, 90%, and 90% for pediatric EHE patients.Conclusion: In the largest study of HVMs to date, we found angiosarcoma has significantly worse overall survival than EHE. Pediatric patients appear to have improved survival and higher rates of resection. Larger studies of HVMs are needed to clearly differentiate tumor types, standardize care, and improve survivorship.


  • Thrombosis in infants in the neonatal intensive care unit: Analysis of a large national database

    by Victoria Robinson, Meredith A. Achey, Uttara P. Nag, Christopher R. Reed, Kristy S. Pahl, Rachel G. Greenberg, Reese H. Clark, Elisabeth T. Tracy


  • Open Access

    The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis

    by Meredith A. Achey, Uttara P. Nag, Victoria L. Robinson, Christopher R. Reed, Gowthami M. Arepally, Jerrold H. Levy, Elisabeth T. Tracy

    Bleeding and thrombosis in critically ill infants and children is a vexing clinical problem. Despite the relatively low incidence of bleeding and thrombosis in the overall pediatric population relative to adults, these critically ill children face unique challenges to hemostasis due to extreme physiologic derangements, exposure of blood to foreign surfaces and membranes, and major vascular endothelial injury or disruption. Caring for pediatric patients on extracorporeal support, recovering from solid organ transplant or invasive surgery, and after major trauma is often complicated by major bleeding or clotting events. As our ability to care for the youngest and sickest of these children increases, the gaps in our understanding of the clinical implications of developmental hemostasis have become increasingly important. We review the current understanding of the development and function of the hemostatic system, including the complex and overlapping interactions of coagulation proteins, platelets, fibrinolysis, and immune mediators from the neonatal period through early childhood and to young adulthood. We then examine scenarios in which our ability to effectively measure and treat coagulation derangements in pediatric patients is limited. In these clinical situations, adult therapies are often extrapolated for use in children without taking age-related differences in pediatric hemostasis into account, leaving clinicians confused and impacting patient outcomes. We discuss the limitations of current coagulation testing in pediatric patients before turning to emerging ideas in the measurement and management of pediatric bleeding and thrombosis. Finally, we highlight opportunities for future research which take into account this developing balance of bleeding and thrombosis in our youngest patients.


  • Using Technology to Deliver Multi-Disciplinary Care to Individuals with Parkinson Disease in Their Homes

    by Earl Dorsey, Meredith Achey, Ryan Korn, Abigail Arky, Christopher Beck, Kevin Biglan, E. Anna Stevenson, William Zhu, Jennifer Mammen, Molly Elson

    Background: Parkinson's disease is a chronic condition that affects ~500,000 Americans. Individuals diagnosed with Parkinson's disease require specialized care for their condition from a neurologist. However, 40% of current Medicare beneficiaries with Parkinson's disease either do not have access to or do not utilize a neurologist. Those who do not see a neurologist are ~20% more likely to fracture a hip, to be placed in a skilled nursing home facility, and to die.


  • National randomized controlled trial of virtual house calls for Parkinson disease

    by Christopher A. Beck, Denise B. Beran, Kevin M. Biglan, Cynthia M. Boyd, E. Ray Dorsey, Peter N. Schmidt, Richard Simone, Allison W. Willis, Nicholas B. Galifianakis, Maya Katz, et al.

    Objective: To determine whether providing remote neurologic care into the homes of people with Parkinson disease (PD) is feasible, beneficial, and valuable. Methods: In a 1-year randomized controlled trial, we compared usual care to usual care supplemented by 4 virtual visits via video conferencing from a remote specialist into patients9 homes. Primary outcome measures were feasibility, as measured by the proportion who completed at least one virtual visit and the proportion of virtual visits completed on time; and efficacy, as measured by the change in the Parkinson9s Disease Questionnaire–39, a quality of life scale. Secondary outcomes included quality of care, caregiver burden, and time and travel savings. Results: A total of 927 individuals indicated interest, 210 were enrolled, and 195 were randomized. Participants had recently seen a specialist (73%) and were largely college-educated (73%) and white (96%). Ninety-five (98% of the intervention group) completed at least one virtual visit, and 91% of 388 virtual visits were completed. Quality of life did not improve in those receiving virtual house calls (0.3 points worse on a 100-point scale; 95% confidence interval [CI] −2.0 to 2.7 points; p = 0.78) nor did quality of care or caregiver burden. Each virtual house call saved patients a median of 88 minutes (95% CI 70–120; p < 0.0001) and 38 miles per visit (95% CI 36–56; p < 0.0001). Conclusions: Providing remote neurologic care directly into the homes of people with PD was feasible and was neither more nor less efficacious than usual in-person care. Virtual house calls generated great interest and provided substantial convenience. ClinicalTrials.gov identifier: NCT02038959. Classification of evidence: This study provides Class III evidence that for patients with PD, virtual house calls from a neurologist are feasible and do not significantly change quality of life compared to in-person visits. The study is rated Class III because it was not possible to mask patients to visit type.


  • National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers

    by E. Ray Dorsey, Meredith A. Achey, Christopher A. Beck, Denise B. Beran, Kevin M. Biglan, Cynthia M. Boyd, Peter N. Schmidt, Richard Simone, Allison W. Willis, Nicholas B. Galifianakis, et al.

    Background: Delivering specialty care remotely directly into people's homes can enhance access for and improve the healthcare of individuals with chronic conditions. However, evidence supporting this approach is limited. Materials and Methods: Connect.Parkinson is a randomized comparative effectiveness study that compares usual care of individuals with Parkinson's disease in the community with usual care augmented by virtual house calls with a Parkinson's disease specialist from 1 of 18 centers nationally. Individuals in the intervention arm receive four virtual visits from a Parkinson's disease specialist over 1 year via secure, Web-based videoconferencing directly into their homes. All study activities, including recruitment, enrollment, and assessments, are conducted remotely. Here we report on interest, feasibility, and barriers to enrollment in this ongoing study. Results: During recruitment, 11,734 individuals visited the study's Web site, and 927 unique individuals submitted electronic interest forms. Two hundred ten individuals from 18 states enrolled in the study from March 2014 to June 2015, and 195 were randomized. Most participants were white (96%) and college educated (73%). Of the randomized participants, 73% had seen a Parkinson's disease specialist within the previous year. Conclusions: Among individuals with Parkinson's disease, national interest in receiving remote specialty care directly into the home is high. Remote enrollment in this care model is feasible but is likely affected by differential access to the Internet.


  • Open Access

    Erratum To: Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial

    by Meredith A. Achey, Christopher A. Beck, Denise B. Beran, Cynthia M. Boyd, Peter N. Schmidt, Allison W. Willis, Sara S. Riggare, Richard B. Simone, Kevin M. Biglan, E. Ray Dorsey